{
    "clinical_study": {
        "@rank": "117633", 
        "acronym": "PAED1", 
        "arm_group": [
            {
                "arm_group_label": "CHF1535 pMDI + AC Plus", 
                "arm_group_type": "Experimental", 
                "description": "Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device"
            }, 
            {
                "arm_group_label": "BDP and Formoterol + AC Plus", 
                "arm_group_type": "Active Comparator", 
                "description": "Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device"
            }
        ], 
        "brief_summary": {
            "textblock": "The rationale is to investigate the systemic availability of BDP/B17MP and formoterol after\n      single oral inhalation of CHF 1535 50/6 pMDI vs the free combination of approved BDP and\n      Formoterol pMDIs, in asthmatic children (5 to 11 years old)."
        }, 
        "brief_title": "Clinical Pharmacology Study of CHF1535 pMDI 50/6 \u00b5g Versus The Free Combination In Asthmatic Children 5-11 Years Old", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male/Female children aged 5-11 years\n\n          -  Written informed consent obtained by parents/legal representative (according to local\n              regulation) and by the minor (age and local regulation permitting).\n\n          -  children with stable asthma on regular treatment with ICS or using short-acting\n             inhaled beta2-agonists as reliever to control asthma symptoms\n\n          -  Forced expiratory volume in one second (FEV1) > 70% of predicted values (% pred)\n             after withholding beta2-agonist treatment for a minimum of 4 h prior to each dose\n             period.\n\n             6. A cooperative attitude and ability to be trained about the proper use of pMDI with\n             a spacer device and compliant to study procedures.\n\n        Exclusion Criteria:\n\n          -  Past or present diagnoses of cardiovascular, renal or liver disease\n\n          -  Known hypersensitivity to the active treatments\n\n          -  Exacerbation of asthma symptoms within the previous 4 weeks\n\n          -  Inability to perform the required breathing technique and blood sampling\n\n          -  Hospitalization due to exacerbation of asthma within 1 month prior to inclusion\n\n          -  Lower respiratory tract infection within 1 month prior to inclusion\n\n          -  Disease (other than asthma) which might influence the outcome of the study\n\n          -  Obesity, i.e. > 97% weight percentile by local standards"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848769", 
            "org_study_id": "CCD-0902-PR-0013"
        }, 
        "intervention": [
            {
                "arm_group_label": "CHF1535 pMDI + AC Plus", 
                "description": "Four inhalations for a total dose of BDP/FF 200/24 mcg", 
                "intervention_name": "CHF1535 pMDI + AC Plus", 
                "intervention_type": "Drug", 
                "other_name": "Fixed combination of BDP and FF 50/6 mcg"
            }, 
            {
                "arm_group_label": "BDP and Formoterol + AC Plus", 
                "description": "Four inhalations for a total dose of BDP 200 mcg", 
                "intervention_name": "BDP + AC Plus", 
                "intervention_type": "Drug", 
                "other_name": "Beclomethasone Dipropionate 50 mcg with Aerochamber Plus"
            }, 
            {
                "arm_group_label": "BDP and Formoterol + AC Plus", 
                "description": "Four inhalations for a total dose of Formoterol 24 mcg", 
                "intervention_name": "Formoterol + AC Plus", 
                "intervention_type": "Drug", 
                "other_name": "Formoterol 6 mcg with Aerochamebr Plus"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Beclomethasone", 
                "Formoterol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Asthma", 
            "ICS+LABA", 
            "Children", 
            "Inhalation", 
            "pMDI"
        ], 
        "lastchanged_date": "May 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "zip": "2100"
                }, 
                "name": "BorneAstmaKlinikken"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-dose, Open-Label, 2-Way Cross-Over, Clinical Pharmacology Study Of Chf 1535 50/6 HFA pMDI (Fixed Combination Of Beclomethasone Dipropionate 50\u00b5g Plus Formoterol Fumarate 6 \u00b5g) Using The Aerochamber Plus\u2122 Spacer Device Versus The Free Combination Of Beclomethasone HFA pMDI And Formoterol HFA pMDI Available On The Market Using The Aerochamber Plus\u2122 Spacer Device In Asthmatic Children", 
        "overall_official": {
            "affiliation": "BorneAstmaKlinikken", 
            "last_name": "Hans Bisgaard, MD DMSci", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Denmark: Danish Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "B17MP (active metabolite of  BDP) systemic exposure as AUC0-t", 
            "measure": "B17MP AUC0-t", 
            "safety_issue": "No", 
            "time_frame": "pre-dose until 8hours post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848769"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "22978252", 
            "citation": "Chawes BL, Piccinno A, Kreiner-M\u00f8ller E, Vissing NH, Poorisrisak P, Mortensen L, Nilson E, Bisgaard A, Dossing A, Deleuran M, Skytt NL, Samandari N, Sergio F, Ciurlia G, Poli G, Acerbi D, Bisgaard H. Pharmacokinetic comparison of inhaled fixed combination vs. the free combination of beclomethasone and formoterol pMDIs in asthmatic children. Br J Clin Pharmacol. 2013 Apr;75(4):1081-8. doi: 10.1111/j.1365-2125.2012.04459.x."
        }, 
        "secondary_outcome": [
            {
                "measure": "B17MP PK profile", 
                "safety_issue": "No", 
                "time_frame": "pre-dose until 8 hours post-dose"
            }, 
            {
                "measure": "BDP PK prolile", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose until 8 hours post-dose"
            }, 
            {
                "measure": "Formoterol PK profile", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose until 8 hours post-dose"
            }, 
            {
                "description": "Plasma potassium to evaluate drug systemic effect", 
                "measure": "Plasma potassium AUC, Cmin, tmin", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose until 8 hours post-dose"
            }, 
            {
                "description": "8h urinary excretion of cortisol and 8h urinary excretion of cortisol normalized for 8h creatinine excretion to evaluate dru systemic effects", 
                "measure": "Urinary Cortisol excretion", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose until 8 hours post-dose"
            }, 
            {
                "description": "Glucose to evaluate the drug systemic effects", 
                "measure": "Glucose in urine", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose until 8 hours post-dose"
            }, 
            {
                "description": "Heart rate to evaluate the drug systemic effects", 
                "measure": "Heart rate Time averaged heart rate value (AUC0-t)/t", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose until 8 hours post-dose"
            }, 
            {
                "description": "Peak respiratory flow as a measure of drug efficacy", 
                "measure": "Spirometry: PEF", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose until 8 hours post-dose"
            }
        ], 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}